Virus-like particle vaccinology, from bench to bedside
MO Mohsen, MF Bachmann - Cellular & molecular immunology, 2022 - nature.com
Virus-like particles (VLPs) have become key tools in biology, medicine and even
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …
RTS, S/AS01 vaccine (Mosquirix™): an overview
MB Laurens - Human vaccines & immunotherapeutics, 2020 - Taylor & Francis
Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
[HTML][HTML] Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled …
Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …
[HTML][HTML] Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus
Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine
is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its …
is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its …
Major findings and recent advances in virus–like particle (VLP)-based vaccines
MO Mohsen, L Zha, G Cabral-Miranda… - Seminars in …, 2017 - Elsevier
Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last
three decades. VLPs constitute versatile tools in vaccine development due to their …
three decades. VLPs constitute versatile tools in vaccine development due to their …
Protein-based antigen presentation platforms for nanoparticle vaccines
B Nguyen, NH Tolia - npj Vaccines, 2021 - nature.com
Modern vaccine design has sought a minimalization approach, moving to the isolation of
antigens from pathogens that invoke a strong neutralizing immune response. This approach …
antigens from pathogens that invoke a strong neutralizing immune response. This approach …
Malaria vaccines: recent advances and new horizons
The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …
[HTML][HTML] Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
MS Datoo, A Dicko, H Tinto, JB Ouédraogo… - The Lancet, 2024 - thelancet.com
Background Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75%
efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina …
efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina …
Malaria vaccines since 2000: progress, priorities, products
PE Duffy, J Patrick Gorres - npj Vaccines, 2020 - nature.com
Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …
The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century
L Stertman, AKE Palm, B Zarnegar… - Human vaccines & …, 2023 - Taylor & Francis
Matrix-M™ adjuvant is a key component of several novel vaccine candidates. The Matrix-M
adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria …
adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria …